Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Immunology Vol. 23; no. 3; pp. 189 - 199
Main Authors Chen, Yanjia, Zhao, Xiaoyu, Zhou, Hao, Zhu, Huanzhang, Jiang, Shibo, Wang, Pengfei
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2023
Nature Publishing Group
Subjects
631/250/2152/2153/1291
631/326/596/2558
631/326/596/4130
Antibodies
Antibodies, Neutralizing
Biomedical and Life Sciences
Biomedicine
Broadly Neutralizing Antibodies
Coronaviruses
COVID-19
COVID-19 vaccines
Drug development
Global economy
Humans
Immunology
Pandemics
Public health
Review
Review Article
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Online AccessGet full text

Cover

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines. The ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a number of variants of concern. In this Review, Wang and colleagues discuss progress in the development and characterization of broadly neutralizing antibodies to SARS-CoV-2, which may lead to new antibody therapeutics and inform the design of next-generation vaccines.
AbstractList Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines.The ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a number of variants of concern. In this Review, Wang and colleagues discuss progress in the development and characterization of broadly neutralizing antibodies to SARS-CoV-2, which may lead to new antibody therapeutics and inform the design of next-generation vaccines.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines. The ancestral strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a number of variants of concern. In this Review, Wang and colleagues discuss progress in the development and characterization of broadly neutralizing antibodies to SARS-CoV-2, which may lead to new antibody therapeutics and inform the design of next-generation vaccines.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus Betacoronavirus. The ancestor strain has evolved into a number of variants of concern, with the Omicron variant of concern now having many distinct sublineages. The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. Many are in preclinical and clinical development, and a few have been approved for emergency use. Here we summarize neutralizing antibodies that target four key regions within the SARS-CoV-2 spike (S) protein, namely the N-terminal domain and the receptor-binding domain in the S1 subunit, and the stem helix region and the fusion peptide region in the S2 subunit. Understanding the characteristics of these broadly neutralizing antibodies will accelerate the development of new antibody therapeutics and provide guidance for the rational design of next-generation vaccines.
Author Zhou, Hao
Jiang, Shibo
Chen, Yanjia
Zhu, Huanzhang
Zhao, Xiaoyu
Wang, Pengfei
Author_xml – sequence: 1
  givenname: Yanjia
  surname: Chen
  fullname: Chen, Yanjia
  organization: State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University
– sequence: 2
  givenname: Xiaoyu
  surname: Zhao
  fullname: Zhao, Xiaoyu
  organization: State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University
– sequence: 3
  givenname: Hao
  orcidid: 0000-0002-0092-7987
  surname: Zhou
  fullname: Zhou, Hao
  organization: Department of Microbiology, Grossman School of Medicine, New York University, College of Medical Technology, Chengdu University of Traditional Chinese Medicine
– sequence: 4
  givenname: Huanzhang
  surname: Zhu
  fullname: Zhu, Huanzhang
  organization: State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University
– sequence: 5
  givenname: Shibo
  orcidid: 0000-0001-8283-7135
  surname: Jiang
  fullname: Jiang, Shibo
  email: shibojiang@fudan.edu.cn
  organization: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University
– sequence: 6
  givenname: Pengfei
  orcidid: 0000-0003-2454-7652
  surname: Wang
  fullname: Wang, Pengfei
  email: pengfei_wang@fudan.edu.cn
  organization: State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36168054$$D View this record in MEDLINE/PubMed
BookMark eNp9UUlr3DAUFiEhW_sHciiGXnpRqmetcymkQ5eQQCBLr0K25BkFj5RKdiD99ZU76WQ55CTB-7b3vgO0HWJwCB0BOQZC1efMgEuJSV1jQqRimG6hfWCSYZAMtjd_SvfQQc63hIAok120RwUIRTjbR2dfUzS2f6iCG4dkev_Hh0VlwuCbaL3L1RCrq5PLKzyPv3BdBraKw9KlajmuTKjamGIw9z6N2eV3aKczfXbvH99DdPP92_X8Jz6_-HE6PznHLWdkwIJQ21nKOysYaahqWdMIBqAEM6YDMyOE844K2VggUvLWGD6jDiy3VjlH6SH6sta9G5uVs60LU3J9l_zKpAcdjdcvJ8Ev9SLe6xkHBkIUgU-PAin-Hl0e9Mrn1vW9CS6OWdcS1EzUxbVAP76C3sYxhbJeQalSg5B8EvzwPNEmyv87F0C9BrQp5pxct4EA0VOZel2mLmXqf2XqyVu9IrV-MIOP01a-f5tK19RcfMLCpafYb7D-AmyDsy0
CitedBy_id crossref_primary_10_1371_journal_pone_0289198
crossref_primary_10_4049_jimmunol_2300315
crossref_primary_10_1038_s41467_024_52808_2
crossref_primary_10_1128_mbio_00679_23
crossref_primary_10_1038_s41421_024_00648_1
crossref_primary_10_3390_ijms24065352
crossref_primary_10_3390_vaccines12111214
crossref_primary_10_1016_j_immuni_2024_08_017
crossref_primary_10_3390_vaccines12101089
crossref_primary_10_1186_s12864_024_09977_7
crossref_primary_10_1128_spectrum_02808_24
crossref_primary_10_3390_ani15030422
crossref_primary_10_1016_j_bsheal_2024_09_002
crossref_primary_10_1128_jvi_00416_24
crossref_primary_10_3389_fimmu_2023_1099629
crossref_primary_10_1016_j_it_2023_09_006
crossref_primary_10_1128_mbio_02477_23
crossref_primary_10_1021_acs_jproteome_3c00569
crossref_primary_10_1039_D1CS01170G
crossref_primary_10_1038_s41392_023_01724_w
crossref_primary_10_1080_1062936X_2024_2306336
crossref_primary_10_1038_s41467_023_39890_8
crossref_primary_10_3389_fimmu_2024_1341313
crossref_primary_10_1073_pnas_2220948120
crossref_primary_10_1177_11769343241272415
crossref_primary_10_1002_jmv_70134
crossref_primary_10_3389_fimmu_2023_1192395
crossref_primary_10_1016_j_smim_2023_101828
crossref_primary_10_3390_biom13091283
crossref_primary_10_3390_ijms25158180
crossref_primary_10_1126_sciimmunol_ade0958
crossref_primary_10_1038_s41579_024_01036_y
crossref_primary_10_1016_j_celrep_2024_114265
crossref_primary_10_3389_fpls_2023_1275228
crossref_primary_10_1016_j_cell_2024_09_043
crossref_primary_10_3389_fimmu_2025_1550279
crossref_primary_10_4049_immunohorizons_2200003
crossref_primary_10_1038_s41467_025_56114_3
crossref_primary_10_1038_s41577_023_00858_w
crossref_primary_10_1038_s41598_024_72491_z
crossref_primary_10_1093_infdis_jiae249
crossref_primary_10_1080_22221751_2023_2244084
crossref_primary_10_3390_vaccines12030218
crossref_primary_10_2222_jsv_73_153
crossref_primary_10_1016_j_ajps_2023_100855
crossref_primary_10_1038_s41598_024_76506_7
crossref_primary_10_2217_nnm_2022_0316
crossref_primary_10_7554_eLife_95708
crossref_primary_10_1186_s12879_024_10345_9
crossref_primary_10_2174_0113816128334441241108050528
crossref_primary_10_1093_glycob_cwaf001
crossref_primary_10_3390_v15030687
crossref_primary_10_3390_vaccines12070738
crossref_primary_10_1002_jmv_29628
crossref_primary_10_3389_fimmu_2023_1252367
crossref_primary_10_1038_s43586_023_00246_7
crossref_primary_10_1021_acs_analchem_4c01165
crossref_primary_10_1038_s41392_024_01917_x
crossref_primary_10_1038_s42003_024_07422_9
crossref_primary_10_1016_j_antiviral_2024_105834
crossref_primary_10_3390_vaccines13010009
crossref_primary_10_1093_infdis_jiad523
crossref_primary_10_1016_j_heliyon_2024_e34925
crossref_primary_10_1080_22221751_2024_2412990
crossref_primary_10_1172_JCI168080
crossref_primary_10_1093_bfgp_elad051
crossref_primary_10_1186_s12985_025_02667_0
crossref_primary_10_3390_v16020217
crossref_primary_10_3389_fmolb_2024_1389548
crossref_primary_10_1016_j_imlet_2024_106887
crossref_primary_10_1186_s12967_025_06162_6
crossref_primary_10_1038_s41392_023_01615_0
crossref_primary_10_3389_fimmu_2023_1307693
crossref_primary_10_1016_j_ejmech_2025_117450
crossref_primary_10_3390_v16030484
crossref_primary_10_1016_j_ebiom_2024_105354
crossref_primary_10_1016_j_virol_2024_110067
crossref_primary_10_1016_j_isci_2024_110326
crossref_primary_10_1016_j_isci_2024_110208
crossref_primary_10_1038_s41392_024_02043_4
crossref_primary_10_1021_acsnano_4c12212
crossref_primary_10_3390_vaccines11020408
crossref_primary_10_1016_j_isci_2024_110354
crossref_primary_10_1038_s41541_024_00817_z
crossref_primary_10_1016_j_isci_2024_110470
crossref_primary_10_1371_journal_ppat_1012383
crossref_primary_10_3390_vaccines12040342
crossref_primary_10_1016_j_ijbiomac_2025_141417
crossref_primary_10_3389_fmolb_2023_1288686
crossref_primary_10_1016_j_cell_2023_04_024
crossref_primary_10_3389_fcimb_2024_1415885
crossref_primary_10_3390_v16030472
crossref_primary_10_1016_j_celbio_2025_100017
crossref_primary_10_1016_j_coviro_2023_101349
crossref_primary_10_1002_jmv_28440
crossref_primary_10_1038_s41467_023_42408_x
crossref_primary_10_1186_s12951_025_03243_y
crossref_primary_10_1016_j_nbt_2023_12_004
crossref_primary_10_3389_fcimb_2023_1239700
crossref_primary_10_1128_mbio_00741_24
crossref_primary_10_3390_vaccines11091451
crossref_primary_10_1128_spectrum_03655_23
crossref_primary_10_1016_j_antiviral_2024_105820
crossref_primary_10_1002_jmv_70071
crossref_primary_10_1080_21645515_2024_2388344
crossref_primary_10_1080_22221751_2024_2412643
crossref_primary_10_3389_fimmu_2023_1273938
crossref_primary_10_1038_s42003_025_07769_7
crossref_primary_10_1016_j_isci_2024_109363
crossref_primary_10_3390_ijms26020587
crossref_primary_10_1016_j_biopha_2025_117936
crossref_primary_10_1155_2024_8871439
crossref_primary_10_1021_acsptsci_5c00122
crossref_primary_10_1111_febs_16777
crossref_primary_10_1021_acsomega_3c07947
crossref_primary_10_1111_imr_13431
crossref_primary_10_3390_epidemiologia5020013
crossref_primary_10_1021_acscentsci_4c00722
crossref_primary_10_1128_jvi_01137_23
crossref_primary_10_1134_S000629792309002X
crossref_primary_10_1128_mbio_03220_23
crossref_primary_10_1371_journal_ppat_1012599
crossref_primary_10_1016_j_vaccine_2025_126744
crossref_primary_10_1360_SSV_2023_0084
crossref_primary_10_1002_jmv_28900
crossref_primary_10_3390_vaccines11111644
crossref_primary_10_1016_j_bbrc_2025_151558
crossref_primary_10_3390_v15061253
crossref_primary_10_1016_j_biopha_2023_115292
crossref_primary_10_7759_cureus_60015
crossref_primary_10_1128_msphere_00393_24
crossref_primary_10_1128_spectrum_02892_23
crossref_primary_10_3390_microorganisms12030617
crossref_primary_10_3390_v15091901
crossref_primary_10_1371_journal_pcbi_1012215
crossref_primary_10_1038_s41586_024_08477_8
crossref_primary_10_7554_eLife_95708_3
crossref_primary_10_3390_vaccines12080914
crossref_primary_10_3390_vaccines12080919
crossref_primary_10_1016_S1473_3099_23_00454_1
crossref_primary_10_1371_journal_ppat_1011804
crossref_primary_10_3390_v15040917
crossref_primary_10_1016_j_tips_2024_10_007
crossref_primary_10_3390_vaccines12040417
crossref_primary_10_1371_journal_ppat_1012456
crossref_primary_10_1021_acs_analchem_3c04372
crossref_primary_10_1016_j_chempr_2024_10_021
crossref_primary_10_1016_j_it_2023_11_006
crossref_primary_10_1002_adhm_202402744
crossref_primary_10_1016_j_cej_2025_159386
crossref_primary_10_1021_acs_analchem_4c04913
crossref_primary_10_1080_14712598_2024_2388186
crossref_primary_10_3389_fimmu_2023_1160065
crossref_primary_10_1016_j_micinf_2024_105461
crossref_primary_10_3389_fcimb_2024_1407261
crossref_primary_10_1038_s41573_023_00672_y
crossref_primary_10_3390_molecules29215206
crossref_primary_10_1016_j_jcvp_2024_100192
crossref_primary_10_3390_ijms25094642
crossref_primary_10_3390_v16020177
crossref_primary_10_1002_rmv_2464
crossref_primary_10_3390_vaccines13030255
crossref_primary_10_1016_j_ijbiomac_2023_125997
crossref_primary_10_1126_scitranslmed_adn0396
crossref_primary_10_1016_j_bbadis_2025_167772
crossref_primary_10_3390_antib13020041
crossref_primary_10_4103_ijmr_ijmr_2591_22
crossref_primary_10_1073_pnas_2414583121
crossref_primary_10_1038_s41551_025_01353_4
crossref_primary_10_1002_mco2_426
crossref_primary_10_1073_pnas_2410529121
crossref_primary_10_1080_21645515_2023_2281733
crossref_primary_10_1371_journal_pone_0298033
crossref_primary_10_1002_adfm_202315442
crossref_primary_10_7717_peerj_17846
crossref_primary_10_7841_ksbbj_2024_39_3_83
crossref_primary_10_3390_vaccines12020129
crossref_primary_10_3390_vaccines11111727
crossref_primary_10_3390_app142311048
crossref_primary_10_1073_pnas_2314518121
crossref_primary_10_1038_s41590_024_01776_2
crossref_primary_10_3390_ijms24020908
crossref_primary_10_1002_jmv_29122
crossref_primary_10_1038_s41467_024_49096_1
crossref_primary_10_1093_procel_pwae007
crossref_primary_10_1111_pbi_14458
crossref_primary_10_1128_jvi_00929_23
crossref_primary_10_3390_ijms25052585
crossref_primary_10_3389_fimmu_2024_1514226
crossref_primary_10_1016_j_biopha_2024_116900
crossref_primary_10_31631_2073_3046_2024_23_6_169_176
crossref_primary_10_31857_S0320972523090026
crossref_primary_10_1093_trstmh_trae060
crossref_primary_10_1208_s12248_025_01043_8
crossref_primary_10_3390_vaccines12090977
crossref_primary_10_1371_journal_ppat_1012650
crossref_primary_10_1128_mbio_00067_24
crossref_primary_10_1088_1742_5468_ad1be7
crossref_primary_10_1126_sciadv_ade3470
crossref_primary_10_1126_sciadv_adk6425
crossref_primary_10_3390_antib12010005
crossref_primary_10_1016_j_bsheal_2025_01_001
Cites_doi 10.1080/22221751.2022.2030200
10.1126/science.abc6952
10.1126/science.abb7269
10.1038/s41579-020-00459-7
10.1016/j.celrep.2021.109771
10.1101/2022.05.13.491770
10.1016/j.cell.2022.03.009
10.1038/s41392-021-00810-1
10.1038/s41586-020-2456-9
10.1038/s41392-021-00740-y
10.1126/science.abf4830
10.1126/science.abc5881
10.1038/s41586-020-2349-y
10.1126/science.abd2321
10.1101/2022.07.18.500332
10.1128/JVI.06540-11
10.1371/journal.ppat.1005578
10.1016/j.immuni.2022.04.003
10.1038/s41577-020-00480-0
10.1126/science.abh1766
10.1080/21645515.2020.1740560
10.1002/prot.25497
10.1126/science.abe3255
10.1038/s41467-021-25331-x
10.1038/s41586-021-03398-2
10.1038/s41586-021-03817-4
10.3390/ijms21124546
10.1038/nrmicro775
10.1038/nature12005
10.1073/pnas.2205784119
10.1016/j.immuni.2020.10.023
10.1016/10.1038/s41564-022-01198-6
10.1126/science.abm8143
10.1126/scitranslmed.abj5413
10.1128/mBio.02473-21
10.1016/j.celrep.2021.109928
10.1038/s41586-020-2548-6
10.1080/22221751.2020.1742076
10.1038/s41586-020-2571-7
10.1038/s41586-021-03908-2
10.1101/2022.07.28.501852
10.1126/science.abq2679
10.1038/s41590-022-01138-w
10.1016/j.chom.2021.04.007
10.1101/2022.01.12.22269023
10.1002/wnan.1697
10.3389/fcimb.2020.587269
10.1038/s41594-020-0480-y
10.1086/655654
10.26508/lsa.202000786
10.1038/s41564-020-0695-z
10.1016/j.celrep.2022.110812
10.1016/j.chom.2021.04.010
10.1126/science.abj3321
10.1016/j.isci.2022.104914
10.1016/S1473-3099(22)00524-2
10.1016/j.str.2021.05.014
10.1126/science.abc2241
10.1126/science.abn8897
10.1038/s41586-020-2380-z
10.1038/s41586-021-03461-y
10.1101/2022.02.01.478504
10.1126/science.abq3773
10.1080/22221751.2021.2011623
10.1016/j.meegid.2020.104502
10.1186/s40249-020-00662-x
10.1038/s41586-020-2852-1
10.1038/s41590-022-01248-5
10.1038/s41401-020-0485-4
10.1038/nrmicro.2016.81
10.1128/cmr.00014-22
10.1038/s41586-020-2012-7
10.3390/v13020202
10.1038/mi.2013.23
10.1016/j.cell.2021.03.029
10.1016/j.bj.2020.11.011
10.1038/s41586-022-04980-y
10.1128/microbiolspec.AID-0012-2013
10.1056/NEJMoa2029849
10.1038/s41586-021-04386-2
10.7326/M20-6976
10.1128/JVI.01762-16
10.1016/j.str.2022.06.004
10.1038/s41586-020-2381-y
10.1038/s41589-021-00832-4
10.1126/scitranslmed.abi9215
10.1038/s41586-021-03807-6
10.1038/s41467-020-20602-5
10.1016/j.cell.2021.03.028
10.1186/s12985-015-0439-5
10.1073/pnas.0400762101
10.1016/j.bpc.2020.106420
10.1016/j.chom.2021.03.005
10.3389/fimmu.2021.752003
10.1038/s41422-022-00612-2
10.1016/j.celrep.2021.109679
10.1038/s41564-022-01155-3
10.1126/sciimmunol.add5446
10.1080/19420862.2021.1922134
10.1016/j.chom.2022.05.001
10.1016/j.isci.2021.102479
10.1126/science.abd0827
10.1016/j.jbc.2021.100306
10.1126/scitranslmed.abj7125
10.1038/s41586-022-05053-w
ContentType Journal Article
Copyright Springer Nature Limited 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2022. Springer Nature Limited.
Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Copyright_xml – notice: Springer Nature Limited 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2022. Springer Nature Limited.
– notice: Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QR
7RV
7T5
7U9
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7N
M7P
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/s41577-022-00784-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Chemoreception Abstracts
Nursing & Allied Health Database
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Public Health
EISSN 1474-1741
EndPage 199
ExternalDocumentID PMC9514166
36168054
10_1038_s41577_022_00784_3
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
.55
0R~
123
29M
36B
39C
3V.
4.4
53G
70F
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8R4
8R5
AAEEF
AARCD
AAWYQ
AAYZH
AAZLF
ABAWZ
ABDBF
ABJNI
ABLJU
ABNNU
ABUWG
ACGFS
ACIWK
ACPRK
ACRPL
ACUHS
ADBBV
ADNMO
AENEX
AEUYN
AFBBN
AFKRA
AFRAH
AFSHS
AGAYW
AGGDT
AGHTU
AHBCP
AHMBA
AHOSX
AHSBF
AIBTJ
AIYXT
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARMCB
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DB5
DU5
EAD
EAP
EBC
EBD
EBS
EE.
EJD
EMB
EMK
EMOBN
EPL
ESX
EX3
EXGXG
F5P
FEDTE
FQGFK
FSGXE
FYUFA
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
IHW
INH
INR
ISR
ITC
L-9
LK8
M1P
M7P
N9A
NAPCQ
NNMJJ
O9-
ODYON
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNR
RNT
RNTTT
SHXYY
SIXXV
SNYQT
SOJ
SV3
TAOOD
TBHMF
TDRGL
TSG
TUS
UKHRP
WOW
X7M
~8M
AAYXX
ABFSG
ACSTC
AEZWR
AFANA
AFHIU
AHWEU
AIXLP
ALPWD
ATHPR
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NFIDA
NPM
7QR
7T5
7U9
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
M7N
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
PUEGO
7X8
5PM
ID FETCH-LOGICAL-c540t-603dfd35fd640b38c4bb6411864aaf1a90055f367bd10775caa593e1d5dd8ee33
IEDL.DBID 7X7
ISSN 1474-1733
1474-1741
IngestDate Thu Aug 21 18:39:21 EDT 2025
Thu Jul 10 22:02:40 EDT 2025
Sat Aug 23 14:28:10 EDT 2025
Thu Apr 03 06:57:02 EDT 2025
Tue Jul 01 04:15:27 EDT 2025
Thu Apr 24 23:10:18 EDT 2025
Fri Feb 21 02:37:46 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License 2022. Springer Nature Limited.
This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-603dfd35fd640b38c4bb6411864aaf1a90055f367bd10775caa593e1d5dd8ee33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0092-7987
0000-0001-8283-7135
0000-0003-2454-7652
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9514166
PMID 36168054
PQID 2781036756
PQPubID 27582
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9514166
proquest_miscellaneous_2718962593
proquest_journals_2781036756
pubmed_primary_36168054
crossref_primary_10_1038_s41577_022_00784_3
crossref_citationtrail_10_1038_s41577_022_00784_3
springer_journals_10_1038_s41577_022_00784_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-03-01
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature reviews. Immunology
PublicationTitleAbbrev Nat Rev Immunol
PublicationTitleAlternate Nat Rev Immunol
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Li (CR19) 2020; 264
Chen (CR51) 2021; 384
Bestle (CR20) 2020; 3
Stadler (CR2) 2003; 1
Barnes (CR41) 2020; 588
Rappazzo (CR68) 2021; 371
Martinez (CR69) 2022; 14
Shi (CR85) 2022
Mitchell, Colwell (CR94) 2018; 86
Yuan (CR64) 2020; 368
Rouet (CR92) 2021; 13
Zhou (CR104) 2022
Westendorf (CR57) 2022
Li (CR100) 2022; 23
Kumar (CR76) 2022
Zhou (CR48) 2022; 376
Wang (CR32) 2021; 593
Banach (CR44) 2021; 37
Woo (CR12) 2012; 86
Wang (CR61) 2022; 608
Suryadevara (CR28) 2021; 184
Moog (CR22) 2014; 7
Dacon (CR86) 2022; 377
Wu (CR73) 2020; 368
Low (CR87) 2022; 377
Cerutti (CR30) 2021; 29
Hansen (CR53) 2020; 369
Yang (CR25) 2020; 9
Yuan (CR72) 2020; 369
Tortorici (CR66) 2021; 597
Cao (CR62) 2022
Liu, Li, Jin, Liu (CR93) 2021; 13
Cerutti (CR34) 2021; 37
Fouchier (CR13) 2004; 101
(CR5) 2020; 5
Jaworski (CR9) 2021; 44
Dai, Gao (CR105) 2021; 21
McCallum (CR33) 2021; 184
Pinto (CR83) 2021; 373
Park (CR49) 2022; 375
Hu, Guo, Zhou, Shi (CR4) 2021; 19
Liu (CR29) 2020; 584
Li, Li, Zhang, Wang (CR16) 2020; 9
Luo (CR63) 2022
Liu (CR106) 2022; 32
Chen (CR90) 2022
Starr (CR47) 2021; 597
Wang (CR58) 2021; 373
Makdasi (CR37) 2021; 36
Alter, Moody (CR26) 2010; 202
Lv (CR71) 2020; 369
Haslwanter (CR39) 2021; 12
Liu (CR70) 2020; 53
Sun (CR88) 2022; 7
Stanfield, Wilson (CR95) 2014
Shi (CR42) 2020; 584
Li (CR78) 2022; 185
Ju (CR77) 2020; 584
Zhou (CR84) 2022; 14
Chen (CR102) 2022; 6
Huang, Yang, Xu, Xu, Liu (CR15) 2020; 41
Raj (CR18) 2013; 495
Ku (CR99) 2022
Bayati, Kumar, Francis, McPherson (CR21) 2021; 296
Mackay, Arden (CR1) 2015; 12
Chi (CR27) 2020; 369
Wang (CR8) 2020; 10
Du (CR101) 2021; 12
Chen, Hotez, Bottazzi (CR52) 2020; 16
Robbiani (CR74) 2020; 584
Cho (CR98) 2021; 13
Turelli (CR60) 2022
Noy-Porat (CR38) 2021; 24
de Wit, van Doremalen, Falzarano, Munster (CR17) 2016; 14
Wang (CR35) 2022; 11
Annavajhala (CR45) 2021; 597
Shrestha, Tedla, Bull (CR82) 2021; 12
Schoof (CR96) 2020; 370
Lok (CR31) 2021; 29
Yang (CR79) 2021; 6
Wang (CR65) 2022; 11
Kim (CR43) 2021; 12
Llanes (CR14) 2020; 21
Oran, Topol (CR10) 2021; 174
Zost (CR54) 2020; 584
Sharma, Ahmad Farouk, Lal (CR11) 2021; 13
Yuan (CR67) 2022; 119
Tan (CR24) 2016; 12
Cao (CR80) 2022; 608
Ai (CR36) 2022; 30
Zhou (CR6) 2020; 579
Pinto (CR56) 2020; 583
De Gasparo (CR97) 2021; 593
Umakanthan (CR3) 2020; 96
Cameroni (CR50) 2022; 602
Fenwick (CR59) 2022
Zhao (CR89) 2022
Qi, Liu, Wang, Zhang (CR103) 2022; 23
Cheeseman (CR23) 2017; 91
Wang (CR40) 2022; 55
Zhou (CR75) 2020; 27
Sheward (CR81) 2022
Wellner (CR91) 2021; 17
Wang (CR46) 2021; 29
Cerutti (CR55) 2021; 29
Kirtipal, Bharadwaj, Kang (CR7) 2020; 85
P Wang (784_CR46) 2021; 29
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. (784_CR5) 2020; 5
SJ Zost (784_CR54) 2020; 584
H Cho (784_CR98) 2021; 13
L Liu (784_CR29) 2020; 584
A Llanes (784_CR14) 2020; 21
DR Martinez (784_CR69) 2022; 14
X Wang (784_CR35) 2022; 11
MY Li (784_CR16) 2020; 9
X Chi (784_CR27) 2020; 369
D Pinto (784_CR83) 2021; 373
Y Cao (784_CR80) 2022; 608
WH Chen (784_CR52) 2020; 16
M Schoof (784_CR96) 2020; 370
L Dai (784_CR105) 2021; 21
F Yang (784_CR25) 2020; 9
M McCallum (784_CR33) 2021; 184
E Cameroni (784_CR50) 2022; 602
MK Annavajhala (784_CR45) 2021; 597
E de Wit (784_CR17) 2016; 14
J Ai (784_CR36) 2022; 30
C Li (784_CR78) 2022; 185
S Luo (784_CR63) 2022
Z Yang (784_CR79) 2021; 6
Z Ku (784_CR99) 2022
M Yuan (784_CR67) 2022; 119
M Yuan (784_CR64) 2020; 368
S Umakanthan (784_CR3) 2020; 96
LB Shrestha (784_CR82) 2021; 12
R Rouet (784_CR92) 2021; 13
X Sun (784_CR88) 2022; 7
Z Li (784_CR100) 2022; 23
J Hansen (784_CR53) 2020; 369
D Bestle (784_CR20) 2020; 3
P Wang (784_CR32) 2021; 593
Y Cao (784_CR62) 2022
M Yuan (784_CR72) 2020; 369
H Zhou (784_CR104) 2022
M Liu (784_CR93) 2021; 13
RA Fouchier (784_CR13) 2004; 101
A Wellner (784_CR91) 2021; 17
W Li (784_CR19) 2020; 264
Z Chen (784_CR90) 2022
A Sharma (784_CR11) 2021; 13
H Liu (784_CR70) 2020; 53
HM Cheeseman (784_CR23) 2017; 91
VS Raj (784_CR18) 2013; 495
Y Chen (784_CR102) 2022; 6
DP Oran (784_CR10) 2021; 174
Y Du (784_CR101) 2021; 12
Q Wang (784_CR61) 2022; 608
CG Rappazzo (784_CR68) 2021; 371
C Moog (784_CR22) 2014; 7
BB Banach (784_CR44) 2021; 37
G Cerutti (784_CR55) 2021; 29
R De Gasparo (784_CR97) 2021; 593
K Stadler (784_CR2) 2003; 1
MY Wang (784_CR8) 2020; 10
P Zhou (784_CR6) 2020; 579
PC Woo (784_CR12) 2012; 86
SM Lok (784_CR31) 2021; 29
JS Low (784_CR87) 2022; 377
IM Mackay (784_CR1) 2015; 12
R Shi (784_CR42) 2020; 584
C Dacon (784_CR86) 2022; 377
K Westendorf (784_CR57) 2022
B Ju (784_CR77) 2020; 584
G Cerutti (784_CR34) 2021; 37
H Qi (784_CR103) 2022; 23
D Haslwanter (784_CR39) 2021; 12
P Turelli (784_CR60) 2022
G Alter (784_CR26) 2010; 202
MA Tortorici (784_CR66) 2021; 597
Z Lv (784_CR71) 2020; 369
Y Huang (784_CR15) 2020; 41
B Hu (784_CR4) 2021; 19
E Makdasi (784_CR37) 2021; 36
CO Barnes (784_CR41) 2020; 588
Y Wu (784_CR73) 2020; 368
P Chen (784_CR51) 2021; 384
P Wang (784_CR65) 2022; 11
S Kumar (784_CR76) 2022
YJ Park (784_CR49) 2022; 375
TN Starr (784_CR47) 2021; 597
DF Robbiani (784_CR74) 2020; 584
DJ Sheward (784_CR81) 2022
LS Mitchell (784_CR94) 2018; 86
C Fenwick (784_CR59) 2022
F Zhao (784_CR89) 2022
D Pinto (784_CR56) 2020; 583
A Bayati (784_CR21) 2021; 296
D Zhou (784_CR75) 2020; 27
G Cerutti (784_CR30) 2021; 29
N Kirtipal (784_CR7) 2020; 85
P Zhou (784_CR84) 2022; 14
W Shi (784_CR85) 2022
Z Wang (784_CR40) 2022; 55
T Zhou (784_CR48) 2022; 376
T Noy-Porat (784_CR38) 2021; 24
C Kim (784_CR43) 2021; 12
JP Jaworski (784_CR9) 2021; 44
Z Liu (784_CR106) 2022; 32
GS Tan (784_CR24) 2016; 12
RL Stanfield (784_CR95) 2014
N Suryadevara (784_CR28) 2021; 184
L Wang (784_CR58) 2021; 373
References_xml – volume: 11
  start-page: 477
  year: 2022
  end-page: 481
  ident: CR35
  article-title: Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2022.2030200
– volume: 369
  start-page: 650
  year: 2020
  end-page: 655
  ident: CR27
  article-title: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abc6952
– volume: 368
  start-page: 630
  year: 2020
  end-page: 633
  ident: CR64
  article-title: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
  publication-title: Science
  doi: 10.1126/science.abb7269
– volume: 19
  start-page: 141
  year: 2021
  end-page: 154
  ident: CR4
  article-title: Characteristics of SARS-CoV-2 and COVID-19
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00459-7
– volume: 37
  start-page: 109771
  year: 2021
  ident: CR44
  article-title: Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109771
– year: 2022
  ident: CR76
  article-title: Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody
  publication-title: bioRxiv
  doi: 10.1101/2022.05.13.491770
– volume: 185
  start-page: 1389
  year: 2022
  end-page: 1401
  ident: CR78
  article-title: Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
  publication-title: Cell
  doi: 10.1016/j.cell.2022.03.009
– volume: 6
  start-page: 378
  year: 2021
  ident: CR79
  article-title: A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
  publication-title: Signal. Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00810-1
– volume: 584
  start-page: 437
  year: 2020
  end-page: 442
  ident: CR74
  article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals
  publication-title: Nature
  doi: 10.1038/s41586-020-2456-9
– volume: 6
  start-page: 315
  year: 2022
  ident: CR102
  article-title: ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
  publication-title: Signal. Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00740-y
– volume: 371
  start-page: 823
  year: 2021
  end-page: 829
  ident: CR68
  article-title: Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
  publication-title: Science
  doi: 10.1126/science.abf4830
– volume: 369
  start-page: 1505
  year: 2020
  end-page: 1509
  ident: CR71
  article-title: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
  publication-title: Science
  doi: 10.1126/science.abc5881
– volume: 583
  start-page: 290
  year: 2020
  end-page: 295
  ident: CR56
  article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
– volume: 369
  start-page: 1119
  year: 2020
  end-page: 1123
  ident: CR72
  article-title: Structural basis of a shared antibody response to SARS-CoV-2
  publication-title: Science
  doi: 10.1126/science.abd2321
– year: 2022
  ident: CR62
  article-title: Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75
  publication-title: bioRxiv
  doi: 10.1101/2022.07.18.500332
– volume: 86
  start-page: 3995
  year: 2012
  end-page: 4008
  ident: CR12
  article-title: Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
  publication-title: J. Virol.
  doi: 10.1128/JVI.06540-11
– volume: 12
  year: 2016
  ident: CR24
  article-title: Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1005578
– volume: 55
  start-page: 998
  year: 2022
  end-page: 1012
  ident: CR40
  article-title: Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.04.003
– volume: 21
  start-page: 73
  year: 2021
  end-page: 82
  ident: CR105
  article-title: Viral targets for vaccines against COVID-19
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00480-0
– volume: 373
  start-page: eabh1766
  year: 2021
  ident: CR58
  article-title: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
  publication-title: Science
  doi: 10.1126/science.abh1766
– volume: 16
  start-page: 1239
  year: 2020
  end-page: 1242
  ident: CR52
  article-title: Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2020.1740560
– volume: 86
  start-page: 697
  year: 2018
  end-page: 706
  ident: CR94
  article-title: Comparative analysis of nanobody sequence and structure data
  publication-title: Proteins
  doi: 10.1002/prot.25497
– volume: 370
  start-page: 1473
  year: 2020
  end-page: 1479
  ident: CR96
  article-title: An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
  publication-title: Science
  doi: 10.1126/science.abe3255
– volume: 12
  year: 2021
  ident: CR101
  article-title: A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-25331-x
– volume: 593
  start-page: 130
  year: 2021
  end-page: 135
  ident: CR32
  article-title: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
  publication-title: Nature
  doi: 10.1038/s41586-021-03398-2
– volume: 597
  start-page: 103
  year: 2021
  end-page: 108
  ident: CR66
  article-title: Broad sarbecovirus neutralization by a human monoclonal antibody
  publication-title: Nature
  doi: 10.1038/s41586-021-03817-4
– volume: 21
  start-page: 4546
  year: 2020
  ident: CR14
  article-title: Betacoronavirus genomes: how genomic information has been used to deal with past outbreaks and the COVID-19 pandemic
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21124546
– volume: 1
  start-page: 209
  year: 2003
  end-page: 218
  ident: CR2
  article-title: SARS–beginning to understand a new virus
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro775
– volume: 495
  start-page: 251
  year: 2013
  end-page: 254
  ident: CR18
  article-title: Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
  publication-title: Nature
  doi: 10.1038/nature12005
– volume: 119
  year: 2022
  ident: CR67
  article-title: A broad and potent neutralization epitope in SARS-related coronaviruses
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2205784119
– volume: 53
  start-page: 1272
  year: 2020
  end-page: 1280
  ident: CR70
  article-title: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.10.023
– year: 2022
  ident: CR59
  article-title: Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
  publication-title: Nat. Microbiol.
  doi: 10.1016/10.1038/s41564-022-01198-6
– volume: 375
  start-page: 449
  year: 2022
  end-page: 454
  ident: CR49
  article-title: Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
  publication-title: Science
  doi: 10.1126/science.abm8143
– volume: 13
  start-page: eabj5413
  year: 2021
  ident: CR98
  article-title: Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abj5413
– volume: 12
  year: 2021
  ident: CR39
  article-title: A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
  publication-title: mBio
  doi: 10.1128/mBio.02473-21
– volume: 37
  start-page: 109928
  year: 2021
  ident: CR34
  article-title: Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109928
– volume: 584
  start-page: 443
  year: 2020
  end-page: 449
  ident: CR54
  article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2548-6
– volume: 9
  start-page: 664
  year: 2020
  end-page: 675
  ident: CR25
  article-title: Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2020.1742076
– volume: 584
  start-page: 450
  year: 2020
  end-page: 456
  ident: CR29
  article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
  publication-title: Nature
  doi: 10.1038/s41586-020-2571-7
– volume: 597
  start-page: 703
  year: 2021
  end-page: 708
  ident: CR45
  article-title: Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York
  publication-title: Nature
  doi: 10.1038/s41586-021-03908-2
– year: 2022
  ident: CR60
  article-title: P2G3 human monoclonal antibody neutralizes SARS-CoV-2 Omicron subvariants including BA.4 and BA.5 and Bebtelovimab escape mutants
  publication-title: bioRxiv
  doi: 10.1101/2022.07.28.501852
– volume: 377
  start-page: 735
  year: 2022
  end-page: 742
  ident: CR87
  article-title: ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies
  publication-title: Science
  doi: 10.1126/science.abq2679
– volume: 23
  start-page: 423
  year: 2022
  end-page: 430
  ident: CR100
  article-title: An engineered bispecific human monoclonal antibody against SARS-CoV-2
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-022-01138-w
– volume: 29
  start-page: 747
  year: 2021
  end-page: 751
  ident: CR46
  article-title: Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.007
– year: 2022
  ident: CR90
  article-title: Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
  publication-title: medRxiv
  doi: 10.1101/2022.01.12.22269023
– volume: 13
  year: 2021
  ident: CR93
  article-title: Nanobody-A versatile tool for cancer diagnosis and therapeutics
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
  doi: 10.1002/wnan.1697
– volume: 10
  start-page: 587269
  year: 2020
  ident: CR8
  article-title: SARS-CoV-2: structure, biology, and structure-based therapeutics development
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2020.587269
– volume: 27
  start-page: 950
  year: 2020
  end-page: 958
  ident: CR75
  article-title: Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-020-0480-y
– volume: 202
  start-page: S315
  year: 2010
  end-page: S322
  ident: CR26
  article-title: The humoral response to HIV-1: new insights, renewed focus
  publication-title: J. Infect. Dis.
  doi: 10.1086/655654
– volume: 3
  year: 2020
  ident: CR20
  article-title: TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
  publication-title: Life Sci. Alliance
  doi: 10.26508/lsa.202000786
– volume: 5
  start-page: 536
  year: 2020
  end-page: 544
  ident: CR5
  article-title: The species : classifying 2019-nCoV and naming it SARS-CoV-2
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0695-z
– year: 2022
  ident: CR57
  article-title: LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2022.110812
– volume: 29
  start-page: 744
  year: 2021
  end-page: 746
  ident: CR31
  article-title: An NTD supersite of attack
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.010
– volume: 373
  start-page: 1109
  year: 2021
  end-page: 1116
  ident: CR83
  article-title: Broad betacoronavirus neutralization by a stem helix-specific human antibody
  publication-title: Science
  doi: 10.1126/science.abj3321
– year: 2022
  ident: CR89
  article-title: Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape
  publication-title: iScience
  doi: 10.1016/j.isci.2022.104914
– year: 2022
  ident: CR81
  article-title: Evasion of neutralizing antibodies by Omicron sublineage BA.2.75
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(22)00524-2
– volume: 29
  start-page: 655
  year: 2021
  end-page: 663
  ident: CR55
  article-title: Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
  publication-title: Structure
  doi: 10.1016/j.str.2021.05.014
– volume: 368
  start-page: 1274
  year: 2020
  end-page: 1278
  ident: CR73
  article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
  publication-title: Science
  doi: 10.1126/science.abc2241
– volume: 376
  start-page: eabn8897
  year: 2022
  ident: CR48
  article-title: Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
  publication-title: Science
  doi: 10.1126/science.abn8897
– volume: 584
  start-page: 115
  year: 2020
  end-page: 119
  ident: CR77
  article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 593
  start-page: 424
  year: 2021
  end-page: 428
  ident: CR97
  article-title: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
  publication-title: Nature
  doi: 10.1038/s41586-021-03461-y
– year: 2022
  ident: CR99
  article-title: Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
  publication-title: bioRxiv
  doi: 10.1101/2022.02.01.478504
– volume: 377
  start-page: 728
  year: 2022
  end-page: 735
  ident: CR86
  article-title: Broadly neutralizing antibodies target the coronavirus fusion peptide
  publication-title: Science
  doi: 10.1126/science.abq3773
– volume: 11
  start-page: 147
  year: 2022
  end-page: 157
  ident: CR65
  article-title: A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2021.2011623
– volume: 85
  start-page: 104502
  year: 2020
  ident: CR7
  article-title: From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses
  publication-title: Infect. Genet. Evol.
  doi: 10.1016/j.meegid.2020.104502
– volume: 9
  year: 2020
  ident: CR16
  article-title: Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues
  publication-title: Infect. Dis. Poverty
  doi: 10.1186/s40249-020-00662-x
– volume: 588
  start-page: 682
  year: 2020
  end-page: 687
  ident: CR41
  article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 96
  start-page: 753
  year: 2020
  end-page: 758
  ident: CR3
  article-title: Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)
  publication-title: Postgrad. Med. J.
– volume: 23
  start-page: 1008
  year: 2022
  end-page: 1020
  ident: CR103
  article-title: The humoral response and antibodies against SARS-CoV-2 infection
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-022-01248-5
– volume: 41
  start-page: 1141
  year: 2020
  end-page: 1149
  ident: CR15
  article-title: Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
  publication-title: Acta Pharmacol. Sin.
  doi: 10.1038/s41401-020-0485-4
– volume: 14
  start-page: 523
  year: 2016
  end-page: 534
  ident: CR17
  article-title: SARS and MERS: recent insights into emerging coronaviruses
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro.2016.81
– year: 2022
  ident: CR104
  article-title: Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/cmr.00014-22
– volume: 579
  start-page: 270
  year: 2020
  end-page: 273
  ident: CR6
  article-title: A pneumonia outbreak associated with a new coronavirus of probable bat origin
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 13
  start-page: 202
  year: 2021
  ident: CR11
  article-title: COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention
  publication-title: Viruses
  doi: 10.3390/v13020202
– volume: 7
  start-page: 46
  year: 2014
  end-page: 56
  ident: CR22
  article-title: Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2013.23
– volume: 184
  start-page: 2316
  year: 2021
  end-page: 2331
  ident: CR28
  article-title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.029
– volume: 44
  start-page: 7
  year: 2021
  end-page: 17
  ident: CR9
  article-title: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
  publication-title: Biomed. J.
  doi: 10.1016/j.bj.2020.11.011
– volume: 608
  start-page: 593
  year: 2022
  end-page: 602
  ident: CR80
  article-title: BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
  publication-title: Nature
  doi: 10.1038/s41586-022-04980-y
– year: 2014
  ident: CR95
  article-title: Antibody structure
  publication-title: Microbiol. Spectr.
  doi: 10.1128/microbiolspec.AID-0012-2013
– volume: 384
  start-page: 229
  year: 2021
  end-page: 237
  ident: CR51
  article-title: SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with Covid-19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2029849
– volume: 602
  start-page: 664
  year: 2022
  end-page: 670
  ident: CR50
  article-title: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
  publication-title: Nature
  doi: 10.1038/s41586-021-04386-2
– volume: 174
  start-page: 655
  year: 2021
  end-page: 662
  ident: CR10
  article-title: The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M20-6976
– volume: 91
  start-page: e01762-16
  year: 2017
  ident: CR23
  article-title: Broadly neutralizing antibodies display potential for prevention of HIV-1 infection of mucosal tissue superior to that of nonneutralizing antibodies
  publication-title: J. Virol.
  doi: 10.1128/JVI.01762-16
– year: 2022
  ident: CR85
  article-title: Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
  publication-title: Structure
  doi: 10.1016/j.str.2022.06.004
– volume: 584
  start-page: 120
  year: 2020
  end-page: 124
  ident: CR42
  article-title: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– volume: 17
  start-page: 1057
  year: 2021
  end-page: 1064
  ident: CR91
  article-title: Rapid generation of potent antibodies by autonomous hypermutation in yeast
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-021-00832-4
– volume: 14
  start-page: eabi9215
  year: 2022
  ident: CR84
  article-title: A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abi9215
– volume: 597
  start-page: 97
  year: 2021
  end-page: 102
  ident: CR47
  article-title: SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
  publication-title: Nature
  doi: 10.1038/s41586-021-03807-6
– volume: 12
  year: 2021
  ident: CR43
  article-title: A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-20602-5
– volume: 184
  start-page: 2332
  year: 2021
  end-page: 2347
  ident: CR33
  article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.028
– volume: 12
  start-page: 222
  year: 2015
  ident: CR1
  article-title: MERS coronavirus: diagnostics, epidemiology and transmission
  publication-title: Virol. J.
  doi: 10.1186/s12985-015-0439-5
– volume: 101
  start-page: 6212
  year: 2004
  end-page: 6216
  ident: CR13
  article-title: A previously undescribed coronavirus associated with respiratory disease in humans
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0400762101
– volume: 264
  start-page: 106420
  year: 2020
  ident: CR19
  article-title: Delving deep into the structural aspects of a furin cleavage site inserted into the spike protein of SARS-CoV-2: a structural biophysical perspective
  publication-title: Biophys. Chem.
  doi: 10.1016/j.bpc.2020.106420
– volume: 29
  start-page: 819
  year: 2021
  end-page: 833
  ident: CR30
  article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.03.005
– volume: 12
  start-page: 752003
  year: 2021
  ident: CR82
  article-title: Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.752003
– volume: 32
  start-page: 269
  year: 2022
  end-page: 287
  ident: CR106
  article-title: A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
  publication-title: Cell Res.
  doi: 10.1038/s41422-022-00612-2
– volume: 36
  start-page: 109679
  year: 2021
  ident: CR37
  article-title: The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109679
– volume: 7
  start-page: 1063
  year: 2022
  end-page: 1074
  ident: CR88
  article-title: Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
  publication-title: Nat. Microb.
  doi: 10.1038/s41564-022-01155-3
– year: 2022
  ident: CR63
  article-title: An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion
  publication-title: Sci. Immuno.
  doi: 10.1126/sciimmunol.add5446
– volume: 13
  start-page: 1922134
  year: 2021
  ident: CR92
  article-title: Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
  publication-title: MAbs
  doi: 10.1080/19420862.2021.1922134
– volume: 30
  start-page: 1077
  year: 2022
  end-page: 1083
  ident: CR36
  article-title: Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2022.05.001
– volume: 24
  start-page: 102479
  year: 2021
  ident: CR38
  article-title: Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
  publication-title: iScience
  doi: 10.1016/j.isci.2021.102479
– volume: 369
  start-page: 1010
  year: 2020
  end-page: 1014
  ident: CR53
  article-title: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
  publication-title: Science
  doi: 10.1126/science.abd0827
– volume: 296
  start-page: 100306
  year: 2021
  ident: CR21
  article-title: SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis
  publication-title: J. Biol. Chem.
  doi: 10.1016/j.jbc.2021.100306
– volume: 14
  start-page: eabj7125
  year: 2022
  ident: CR69
  article-title: A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abj7125
– volume: 608
  start-page: 603
  year: 2022
  end-page: 608
  ident: CR61
  article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
  publication-title: Nature
  doi: 10.1038/s41586-022-05053-w
– volume: 369
  start-page: 1505
  year: 2020
  ident: 784_CR71
  publication-title: Science
  doi: 10.1126/science.abc5881
– volume: 7
  start-page: 46
  year: 2014
  ident: 784_CR22
  publication-title: Mucosal Immunol.
  doi: 10.1038/mi.2013.23
– volume: 85
  start-page: 104502
  year: 2020
  ident: 784_CR7
  publication-title: Infect. Genet. Evol.
  doi: 10.1016/j.meegid.2020.104502
– volume: 86
  start-page: 3995
  year: 2012
  ident: 784_CR12
  publication-title: J. Virol.
  doi: 10.1128/JVI.06540-11
– year: 2022
  ident: 784_CR57
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2022.110812
– volume: 373
  start-page: eabh1766
  year: 2021
  ident: 784_CR58
  publication-title: Science
  doi: 10.1126/science.abh1766
– volume: 14
  start-page: eabi9215
  year: 2022
  ident: 784_CR84
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abi9215
– volume: 101
  start-page: 6212
  year: 2004
  ident: 784_CR13
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0400762101
– volume: 37
  start-page: 109928
  year: 2021
  ident: 784_CR34
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109928
– volume: 174
  start-page: 655
  year: 2021
  ident: 784_CR10
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M20-6976
– volume: 185
  start-page: 1389
  year: 2022
  ident: 784_CR78
  publication-title: Cell
  doi: 10.1016/j.cell.2022.03.009
– volume: 584
  start-page: 443
  year: 2020
  ident: 784_CR54
  publication-title: Nature
  doi: 10.1038/s41586-020-2548-6
– volume: 6
  start-page: 315
  year: 2022
  ident: 784_CR102
  publication-title: Signal. Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00740-y
– volume: 584
  start-page: 437
  year: 2020
  ident: 784_CR74
  publication-title: Nature
  doi: 10.1038/s41586-020-2456-9
– volume: 296
  start-page: 100306
  year: 2021
  ident: 784_CR21
  publication-title: J. Biol. Chem.
  doi: 10.1016/j.jbc.2021.100306
– volume: 11
  start-page: 147
  year: 2022
  ident: 784_CR65
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2021.2011623
– volume: 593
  start-page: 424
  year: 2021
  ident: 784_CR97
  publication-title: Nature
  doi: 10.1038/s41586-021-03461-y
– volume: 368
  start-page: 630
  year: 2020
  ident: 784_CR64
  publication-title: Science
  doi: 10.1126/science.abb7269
– volume: 14
  start-page: eabj7125
  year: 2022
  ident: 784_CR69
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abj7125
– volume: 29
  start-page: 747
  year: 2021
  ident: 784_CR46
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.007
– volume: 377
  start-page: 735
  year: 2022
  ident: 784_CR87
  publication-title: Science
  doi: 10.1126/science.abq2679
– volume: 13
  start-page: 202
  year: 2021
  ident: 784_CR11
  publication-title: Viruses
  doi: 10.3390/v13020202
– volume: 44
  start-page: 7
  year: 2021
  ident: 784_CR9
  publication-title: Biomed. J.
  doi: 10.1016/j.bj.2020.11.011
– year: 2022
  ident: 784_CR76
  publication-title: bioRxiv
  doi: 10.1101/2022.05.13.491770
– volume: 6
  start-page: 378
  year: 2021
  ident: 784_CR79
  publication-title: Signal. Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00810-1
– volume: 588
  start-page: 682
  year: 2020
  ident: 784_CR41
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 55
  start-page: 998
  year: 2022
  ident: 784_CR40
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.04.003
– volume: 19
  start-page: 141
  year: 2021
  ident: 784_CR4
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00459-7
– year: 2022
  ident: 784_CR63
  publication-title: Sci. Immuno.
  doi: 10.1126/sciimmunol.add5446
– volume: 21
  start-page: 4546
  year: 2020
  ident: 784_CR14
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21124546
– year: 2022
  ident: 784_CR81
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(22)00524-2
– volume: 597
  start-page: 97
  year: 2021
  ident: 784_CR47
  publication-title: Nature
  doi: 10.1038/s41586-021-03807-6
– volume: 202
  start-page: S315
  year: 2010
  ident: 784_CR26
  publication-title: J. Infect. Dis.
  doi: 10.1086/655654
– volume: 11
  start-page: 477
  year: 2022
  ident: 784_CR35
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2022.2030200
– volume: 584
  start-page: 120
  year: 2020
  ident: 784_CR42
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– volume: 579
  start-page: 270
  year: 2020
  ident: 784_CR6
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 29
  start-page: 819
  year: 2021
  ident: 784_CR30
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.03.005
– volume: 593
  start-page: 130
  year: 2021
  ident: 784_CR32
  publication-title: Nature
  doi: 10.1038/s41586-021-03398-2
– volume: 384
  start-page: 229
  year: 2021
  ident: 784_CR51
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2029849
– volume: 3
  year: 2020
  ident: 784_CR20
  publication-title: Life Sci. Alliance
  doi: 10.26508/lsa.202000786
– volume: 24
  start-page: 102479
  year: 2021
  ident: 784_CR38
  publication-title: iScience
  doi: 10.1016/j.isci.2021.102479
– volume: 12
  start-page: 752003
  year: 2021
  ident: 784_CR82
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.752003
– volume: 12
  start-page: 222
  year: 2015
  ident: 784_CR1
  publication-title: Virol. J.
  doi: 10.1186/s12985-015-0439-5
– volume: 13
  start-page: eabj5413
  year: 2021
  ident: 784_CR98
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abj5413
– volume: 184
  start-page: 2332
  year: 2021
  ident: 784_CR33
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.028
– volume: 30
  start-page: 1077
  year: 2022
  ident: 784_CR36
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2022.05.001
– volume: 37
  start-page: 109771
  year: 2021
  ident: 784_CR44
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109771
– volume: 369
  start-page: 1010
  year: 2020
  ident: 784_CR53
  publication-title: Science
  doi: 10.1126/science.abd0827
– volume: 23
  start-page: 423
  year: 2022
  ident: 784_CR100
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-022-01138-w
– year: 2022
  ident: 784_CR89
  publication-title: iScience
  doi: 10.1016/j.isci.2022.104914
– volume: 21
  start-page: 73
  year: 2021
  ident: 784_CR105
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00480-0
– volume: 375
  start-page: 449
  year: 2022
  ident: 784_CR49
  publication-title: Science
  doi: 10.1126/science.abm8143
– volume: 608
  start-page: 593
  year: 2022
  ident: 784_CR80
  publication-title: Nature
  doi: 10.1038/s41586-022-04980-y
– volume: 29
  start-page: 744
  year: 2021
  ident: 784_CR31
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.04.010
– volume: 29
  start-page: 655
  year: 2021
  ident: 784_CR55
  publication-title: Structure
  doi: 10.1016/j.str.2021.05.014
– year: 2022
  ident: 784_CR59
  publication-title: Nat. Microbiol.
  doi: 10.1016/10.1038/s41564-022-01198-6
– volume: 17
  start-page: 1057
  year: 2021
  ident: 784_CR91
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-021-00832-4
– volume: 495
  start-page: 251
  year: 2013
  ident: 784_CR18
  publication-title: Nature
  doi: 10.1038/nature12005
– volume: 16
  start-page: 1239
  year: 2020
  ident: 784_CR52
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2020.1740560
– volume: 13
  start-page: 1922134
  year: 2021
  ident: 784_CR92
  publication-title: MAbs
  doi: 10.1080/19420862.2021.1922134
– volume: 96
  start-page: 753
  year: 2020
  ident: 784_CR3
  publication-title: Postgrad. Med. J.
– year: 2022
  ident: 784_CR85
  publication-title: Structure
  doi: 10.1016/j.str.2022.06.004
– year: 2022
  ident: 784_CR60
  publication-title: bioRxiv
  doi: 10.1101/2022.07.28.501852
– year: 2014
  ident: 784_CR95
  publication-title: Microbiol. Spectr.
  doi: 10.1128/microbiolspec.AID-0012-2013
– volume: 23
  start-page: 1008
  year: 2022
  ident: 784_CR103
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-022-01248-5
– volume: 602
  start-page: 664
  year: 2022
  ident: 784_CR50
  publication-title: Nature
  doi: 10.1038/s41586-021-04386-2
– volume: 369
  start-page: 1119
  year: 2020
  ident: 784_CR72
  publication-title: Science
  doi: 10.1126/science.abd2321
– volume: 12
  year: 2021
  ident: 784_CR43
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-20602-5
– year: 2022
  ident: 784_CR99
  publication-title: bioRxiv
  doi: 10.1101/2022.02.01.478504
– volume: 584
  start-page: 450
  year: 2020
  ident: 784_CR29
  publication-title: Nature
  doi: 10.1038/s41586-020-2571-7
– year: 2022
  ident: 784_CR62
  publication-title: bioRxiv
  doi: 10.1101/2022.07.18.500332
– volume: 41
  start-page: 1141
  year: 2020
  ident: 784_CR15
  publication-title: Acta Pharmacol. Sin.
  doi: 10.1038/s41401-020-0485-4
– volume: 376
  start-page: eabn8897
  year: 2022
  ident: 784_CR48
  publication-title: Science
  doi: 10.1126/science.abn8897
– volume: 608
  start-page: 603
  year: 2022
  ident: 784_CR61
  publication-title: Nature
  doi: 10.1038/s41586-022-05053-w
– volume: 119
  year: 2022
  ident: 784_CR67
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2205784119
– volume: 597
  start-page: 703
  year: 2021
  ident: 784_CR45
  publication-title: Nature
  doi: 10.1038/s41586-021-03908-2
– volume: 9
  start-page: 664
  year: 2020
  ident: 784_CR25
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2020.1742076
– volume: 264
  start-page: 106420
  year: 2020
  ident: 784_CR19
  publication-title: Biophys. Chem.
  doi: 10.1016/j.bpc.2020.106420
– volume: 9
  year: 2020
  ident: 784_CR16
  publication-title: Infect. Dis. Poverty
  doi: 10.1186/s40249-020-00662-x
– volume: 584
  start-page: 115
  year: 2020
  ident: 784_CR77
  publication-title: Nature
  doi: 10.1038/s41586-020-2380-z
– volume: 369
  start-page: 650
  year: 2020
  ident: 784_CR27
  publication-title: Science
  doi: 10.1126/science.abc6952
– volume: 12
  year: 2016
  ident: 784_CR24
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1005578
– volume: 13
  year: 2021
  ident: 784_CR93
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
  doi: 10.1002/wnan.1697
– volume: 12
  year: 2021
  ident: 784_CR101
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-25331-x
– volume: 14
  start-page: 523
  year: 2016
  ident: 784_CR17
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro.2016.81
– volume: 12
  year: 2021
  ident: 784_CR39
  publication-title: mBio
  doi: 10.1128/mBio.02473-21
– volume: 371
  start-page: 823
  year: 2021
  ident: 784_CR68
  publication-title: Science
  doi: 10.1126/science.abf4830
– volume: 5
  start-page: 536
  year: 2020
  ident: 784_CR5
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-020-0695-z
– volume: 368
  start-page: 1274
  year: 2020
  ident: 784_CR73
  publication-title: Science
  doi: 10.1126/science.abc2241
– volume: 583
  start-page: 290
  year: 2020
  ident: 784_CR56
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
– volume: 86
  start-page: 697
  year: 2018
  ident: 784_CR94
  publication-title: Proteins
  doi: 10.1002/prot.25497
– year: 2022
  ident: 784_CR90
  publication-title: medRxiv
  doi: 10.1101/2022.01.12.22269023
– year: 2022
  ident: 784_CR104
  publication-title: Clin. Microbiol. Rev.
  doi: 10.1128/cmr.00014-22
– volume: 370
  start-page: 1473
  year: 2020
  ident: 784_CR96
  publication-title: Science
  doi: 10.1126/science.abe3255
– volume: 184
  start-page: 2316
  year: 2021
  ident: 784_CR28
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.029
– volume: 36
  start-page: 109679
  year: 2021
  ident: 784_CR37
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.109679
– volume: 91
  start-page: e01762-16
  year: 2017
  ident: 784_CR23
  publication-title: J. Virol.
  doi: 10.1128/JVI.01762-16
– volume: 10
  start-page: 587269
  year: 2020
  ident: 784_CR8
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2020.587269
– volume: 7
  start-page: 1063
  year: 2022
  ident: 784_CR88
  publication-title: Nat. Microb.
  doi: 10.1038/s41564-022-01155-3
– volume: 1
  start-page: 209
  year: 2003
  ident: 784_CR2
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/nrmicro775
– volume: 32
  start-page: 269
  year: 2022
  ident: 784_CR106
  publication-title: Cell Res.
  doi: 10.1038/s41422-022-00612-2
– volume: 377
  start-page: 728
  year: 2022
  ident: 784_CR86
  publication-title: Science
  doi: 10.1126/science.abq3773
– volume: 597
  start-page: 103
  year: 2021
  ident: 784_CR66
  publication-title: Nature
  doi: 10.1038/s41586-021-03817-4
– volume: 53
  start-page: 1272
  year: 2020
  ident: 784_CR70
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.10.023
– volume: 27
  start-page: 950
  year: 2020
  ident: 784_CR75
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-020-0480-y
– volume: 373
  start-page: 1109
  year: 2021
  ident: 784_CR83
  publication-title: Science
  doi: 10.1126/science.abj3321
SSID ssj0016174
Score 2.7115908
SecondaryResourceType review_article
Snippet Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged pathogenic human coronavirus that belongs to the sarbecovirus lineage of the...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 189
SubjectTerms 631/250/2152/2153/1291
631/326/596/2558
631/326/596/4130
Antibodies
Antibodies, Neutralizing
Biomedical and Life Sciences
Biomedicine
Broadly Neutralizing Antibodies
Coronaviruses
COVID-19
COVID-19 vaccines
Drug development
Global economy
Humans
Immunology
Pandemics
Public health
Review
Review Article
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccines
Title Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
URI https://link.springer.com/article/10.1038/s41577-022-00784-3
https://www.ncbi.nlm.nih.gov/pubmed/36168054
https://www.proquest.com/docview/2781036756
https://www.proquest.com/docview/2718962593
https://pubmed.ncbi.nlm.nih.gov/PMC9514166
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dSxwxEB9apUWQ0l4_vNZKCn1rg5dLNrv7VOyhSItStJZ7W7KbBA9kV907Qf_6zmRzK1epL7sPyW4-Jh-_yUx-A_BZ5V55bzS3mUi4qqzmuU9xMdSJEyW5HYboDUfH-vBM_Zgm03jg1ka3yuWaGBZq21R0Rr47TjOBq22a6G-XV5yiRpF1NYbQeArrRF1GLl3ptFe4CLoHq7JKFReplPHSzEhmuy1uXFgl8mWnXVJxuboxPUCbD50m_7Gchg3p4CW8iEiS7XWifwVPXD2AZ11sydsBPD-KVvMBbHZnc6y7cvQafqLubezFLavdIhx03GEBDLt4VjbkVMjmDTvdOznlk-YPH2OCZeGeFgsB_VhFpAfmZna9aF37Bs4O9n9PDnkMqsArBGdzrkfSeisTb7UalTKrVFlqhWqGVsZ4YXJi5fLY0aUVRI9XGZPk0gmbWJs5J-VbWKub2m0Bc3LsEV1afBkiujdOjRX-IvGiQq1KD0Ese7SoIuM4Bb64KILlW2ZFJ4UCpVAEKRRyCF_6by47vo1Hc28vBVXEudcW9yNlCJ_6ZJw1ZAoxtWsWlEdkOal--It3nVz74qQWOkMkO4R0ReJ9BmLkXk2pZ-eBmRvhKgJcLPfrcmzcV-v_rXj_eCs-wAbFuO8c37ZhbX69cB8RCc3LnTDc8ZlNxA6sf98__nXyFyT4BTs
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NnfiQEILyVRhgJHgCa3XsOMkDQmNs6uhaoX2gvQUntkWlKRlLCyp_FH8j5zjJVCb2tqc-2Ikb3_n8O9_5dwCvRWKFtUpSHbOQilxLmtgIjaEMDctc2mFdvWEylaNj8fkkPFmDP-1dGJdW2drE2lDrMndn5JtBFDO0tlEoP5z9oK5qlIuutiU0vFqMzfIXumzV-71PKN83QbC7c7Q9ok1VAZojOplTOeTaah5aLcUw43EuskwKxNlSKGWZShwtlcWRMs0cP1yuVJhww3SodWyMOwBFk78uOLoyPVj_uDP9ctDFLaTnfWYiEpRFnDfXdIY83qxwq8RJcNnzbl8WlK9uhZfw7eU0zX9itfUWuHsP7jbYlWx5ZbsPa6boww1fzXLZh5uTJk7fhzv-NJD4S04PYIzevtKnS1KYRX208hsHICjUWVa6NEYyL8nh1sEh3S6_0gAbNKlvhpG6hCDJHc2C-jk7X1SmegjH1zLhj6BXlIV5AsTwwCKe1fijHLW-MiIQ-IrQshz9ODkA1s5omjcc567Uxmlax9p5nHoppCiFtJZCygfwtnvmzDN8XNl7oxVU2qz2Kr3QzQG86ppxnbrgiypMuXB9WJw4ZxNf8djLtRuOSyZjxM4DiFYk3nVwHOCrLcXse80FjgAZITWO-67VjYu_9f-veHr1V7yEW6OjyX66vzcdP4PbAeI6n3a3Ab35-cI8Rxw2z140yk_g23Wvt7-DbUEZ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9NQ0xICEH56hhgJHgCq3XsOOkDQtNGtVE2IcZQ3zIntkWlKdnWFlT-NP467pykU5nY257yYCeOfR_-ne98B_BaDbzy3mhuUxFzVVjNBz5BZahjJ3IKOwzVGw4O9d6x-jSOx2vwp70LQ2GVrU4MitpWBZ2R96IkFahtk1j3fBMW8WV3-OHsnFMFKfK0tuU0ahYZucUvNN-m7_d3kdZvomj48dvOHm8qDPACkcqM67603srYW636uUwLledaIebWyhgvzIBSVHkcNbeCcsUVxsQD6YSNrU2do8NQVP-3EhkLkrFkvDT2yGwIHm2VKC4SKZsLO32Z9qa4aeJyUBw97dCKy9VN8QrSvRqw-Y_XNmyGw_twr0GxbLtmuwew5soO3K7rWi46sHHQeOw7cLc-F2T1daeHMEK739jTBSvdPByy_MYBGJJ3klcU0MhmFTva_nrEd6rvPMIGy8IdMRaKCbKCEi6Yn5OL-dRNH8HxjSz3Y1gvq9I9BeZk5BHZWnwYSrJvnIoUfiL2okCLTndBtCuaFU22cyq6cZoFr7tMs5oKGVIhC1TIZBfeLt85q3N9XNt7qyVU1sj9NLvk0i68WjajxJIbxpSumlMfkQ7I7MRPPKnpuhxOaqFTRNFdSFYovuxA2cBXW8rJj5AVHKEygmsc913LG5e_9f9ZbF4_i5ewgVKWfd4_HD2DOxECvDr-bgvWZxdz9xwB2Sx_ETifwclNi9pfIotD6Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Broadly+neutralizing+antibodies+to+SARS-CoV-2+and+other+human+coronaviruses&rft.jtitle=Nature+reviews.+Immunology&rft.au=Chen%2C+Yanjia&rft.au=Zhao%2C+Xiaoyu&rft.au=Zhou%2C+Hao&rft.au=Zhu%2C+Huanzhang&rft.date=2023-03-01&rft.issn=1474-1741&rft.eissn=1474-1741&rft.volume=23&rft.issue=3&rft.spage=189&rft_id=info:doi/10.1038%2Fs41577-022-00784-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-1733&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-1733&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-1733&client=summon